13F Holdings
中文EN

MRNA Moderna, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1682852 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.1%
TTM net income YoY10.5%
TTM EPS YoY12.7%
Revenue 3-yr CAGR-34.8%
Net income 3-yr CAGR—

Margins

Gross margin28.0%
Operating margin-116.0%
Net margin-110.5%
FCF margin-78.0%
EBITDA margin-106.6%

Returns

ROE-34.5%
ROA-21.8%
ROIC (approx.)-33.4%
Asset turnover0.20x

Leverage & solvency

Liabilities / assets49.2%
Debt / equity0.00x
Current ratio3.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue7.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.94B$3.24B$6.85B$19.26B$18.47B
Cost of revenue$868.00M$1.46B$4.69B$5.42B$2.62B
Gross profit$1.08B$1.77B$2.15B$13.85B$15.85B
R&D expense$3.13B$4.54B$4.84B$3.29B$1.99B
SG&A expense$1.02B$1.17B$1.55B$1.13B$567.00M
Operating income-$3.07B-$3.94B-$4.24B$9.42B$13.30B
Pretax income-$2.77B-$3.61B-$3.94B$9.57B$13.29B
Income tax$54.00M-$46.00M$772.00M$1.21B$1.08B
Net income-$2.82B-$3.56B-$4.71B$8.36B$12.20B
EBITDA-$2.86B-$3.76B-$3.62B$9.77B$13.53B
EPS (basic)-7.26-9.28-12.3321.2630.31
EPS (diluted)-7.26-9.28-12.3320.1228.29
Weighted avg. shares (diluted)389.00M384.00M382.00M416.00M431.00M
Balance sheet
Cash & equivalents$2.60B$1.93B$2.91B$3.22B$6.86B
Short-term investments$3.20B$5.10B$5.70B$6.70B$3.88B
Receivables$184.00M$358.00M$892.00M$1.39B$3.17B
Inventory$153.00M$117.00M$202.00M$949.00M$1.44B
Current assets$6.54B$8.10B$10.32B$13.43B$16.07B
PP&E, net$2.13B$2.20B$1.95B$2.02B$1.24B
Goodwill$52.00M$52.00M$52.00M$0—
Intangibles$45.00M$40.00M$44.00M$0—
Total assets$12.34B$14.14B$18.43B$25.86B$24.67B
Current liabilities$1.99B$2.21B$3.02B$4.92B$9.13B
Long-term debt$590.00M$0———
Total debt$590.00M$0———
Total liabilities$3.69B$3.24B$4.57B$6.74B$10.52B
Shareholders' equity$8.65B$10.90B$13.85B$19.12B$14.14B
Net debt-$2.00B-$1.93B———
Shares outstanding394.00M386.00M382.00M385.00M403.00M
Cash flow statement
Operating cash flow-$1.87B-$3.00B-$3.12B$4.98B$13.62B
Capital expenditure$192.00M$1.05B$707.00M$400.00M$284.00M
Free cash flow-$2.06B-$4.05B-$3.83B$4.58B$13.34B
Investing cash flow$1.95B$1.95B$4.21B-$5.18B-$8.52B
Financing cash flow$593.00M$56.00M-$1.38B-$3.45B-$873.00M
Depreciation & amortization$211.00M$185.00M$617.00M$348.00M$232.00M
Stock-based compensation$483.00M$429.00M$305.00M$226.00M$142.00M
Share buybacks$2.00M$0$1.15B$3.33B$857.00M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.